Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ; Australasian Gastro-Intestinal Trials Group. Clarke SJ, et al. Among authors: brown c. Eur J Cancer. 2011 Aug;47(12):1826-36. doi: 10.1016/j.ejca.2011.04.024. Epub 2011 Jun 12. Eur J Cancer. 2011. PMID: 21665462 Clinical Trial.
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pujade-Lauraine E, et al. Among authors: brown c. J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498395 Clinical Trial.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E; Gynecologic Cancer Intergroup. Kurtz JE, et al. Among authors: brown c. Ann Oncol. 2011 Nov;22(11):2417-2423. doi: 10.1093/annonc/mdr001. Epub 2011 Mar 14. Ann Oncol. 2011. PMID: 21402619 Free article. Clinical Trial.
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Lee CK, et al. Among authors: brown c. Br J Cancer. 2011 Jul 26;105(3):360-5. doi: 10.1038/bjc.2011.256. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750553 Free PMC article. Clinical Trial.
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ. Lee CK, et al. Among authors: brown c. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42. doi: 10.1093/jnci/djr282. Epub 2011 Aug 11. J Natl Cancer Inst. 2011. PMID: 21840849
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: brown c. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group. Goldstein D, et al. Among authors: brown c. Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134511 Free PMC article. Clinical Trial.
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP. Wagner U, et al. Among authors: brown c. Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26. Br J Cancer. 2012. PMID: 22836511 Free PMC article. Clinical Trial.
12,656 results
You have reached the last available page of results. Please see the User Guide for more information.